Axcelead DDP and Astellas Unite to Pioneer Targeted Protein Degrader Drug Discovery

Fujisawa, Japan – In a groundbreaking step toward revolutionizing drug discovery, Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) has forged an innovative partnership with Astellas Pharma, Inc., a leading global pharmaceutical company. This collaboration aims to explore and develop next-generation targeted protein degraders—game-changing compounds in the realm of small-molecule therapies.

Axcelead DDP, headquartered in Kanagawa, Japan, is at the forefront of targeted protein degradation, which is widely regarded as the next frontier in drug discovery. The company’s cutting-edge DegLead™ Platform provides a comprehensive solution to the most intricate challenges in this field. From pioneering synthetic technologies for rapid degrader development to high-throughput screening systems and advanced profiling assays, the DegLead™ Platform is a powerhouse of innovation.

Under the newly inked agreement, Axcelead DDP will leverage its DegLead™ Platform to support Astellas in uncovering breakthrough drug candidates in the targeted protein degrader space.

Expressing his enthusiasm for the collaboration, Dr. Kengo Okada, Representative Director and CEO of Axcelead DDP, stated:

"This partnership with Astellas is a testament to the transformative potential of our proprietary DegLead™ Platform. Their recognition of our technology reinforces our belief that Axcelead DDP is setting a new benchmark in drug discovery services. We remain committed to pushing the boundaries of innovation, delivering tailored solutions, and driving the evolution of pharmaceutical research through cutting-edge advancements."

This partnership signals not just a shared vision for the future of medicine but a commitment to addressing unmet needs in healthcare. By joining forces, Axcelead DDP and Astellas are poised to redefine possibilities in targeted protein degradation and open new doors to life-changing treatments.